Clinical trials: Type Two Diabetes Mellitus
Hypertension
Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
- Trial name
- NCT00160225
- Testing
- Daglutril
- Where
- Italy
- Sponsor
- Solvay Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7%…
- Trial name
- NCT01215435
- Testing
- biphasic insulin aspart 30
- Where
- Iran
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30 (NN-X14Mix30) and biphasic insulin aspart 50 (NN-X14Mix5050) in subjects with type…
- Trial name
- NCT01620424
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 50
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656
The purpose of this study is to evaluate the effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656
- Trial name
- NCT01083212
- Testing
- AZD1656, Gemfibrozil
- Where
- 3 sites in Sweden
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124560
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Hypertension, Diabete Type 2
Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers
This clinical trial is a two-arm, open-label, single-sequence, multiple oral dosings, cross-over design clinical trial to evaluate the safety and pharmacokinetic characteristics of HL1113-R1 and HL1113-R2 in healthy adult…
- Trial name
- NCT07598968
- Testing
- Test group 1, Test group 2
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Type1diabetes
Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.
This is a study of the Minimed 670G 4.0 insulin pump, assessing the efficacy of the Advanced Hybrid Closed Loop (AHCL) algorithm in controlling blood glucose levels in Type 1 Diabetes.
- Trial name
- NCT04073576
- Testing
- AHCL, SAP+PLGM
- Where
- New Zealand
- Volunteers
- 60 people
- Sponsor
- Christchurch Clinical Studies Trust Ltd
Diabetes Mellitus, Type 1
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1…
- Trial name
- IOOZ (NCT00487240)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Levemir
- Where
- 28 sites in United States, Argentina and 7 more
- Volunteers
- 387 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to compare pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (the exposure of the trial drug in the body) properties of insulin…
- Trial name
- NCT02536859
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Hypertension, Diabete Type 2
Clinical Trial to Evaluate the Pharmacokinetics and Safety Between the Single Administration of HL1113 and the Concomitant Administration of HL1113R1 and HL1113R2 for Healthy Subjects in Fasting State
This clinical trial is a randomized, open-label, single oral dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the single administration of HL1113 and the concomitant…
- Trial name
- NCT07568652
- Testing
- Test group 1, Test group 2
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Diabetes Mellitus
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs).
- Trial name
- NCT00348374
- Testing
- Insulin Lispro, Exubera
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 191 people
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the safety and tolerability of two dose levels of a new insulin glargine formulation in a once-daily multiple dosing regimen Secondary Objective: To compare the pharmacokinetic and pharmacodynamic…
- Trial name
- NCT01349855
- Testing
- Insulin glargine HOE901
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
DS-1150b is being developed by Daiichi Sankyo for the treatment of Type 2 Diabetes Mellitus. This is a Phase I, single-blind (subjects and principal investigator blinded, Sponsor unblinded), placebo-controlled, randomized…
- Trial name
- NCT02004678
- Testing
- DS-1150b
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Effect of BKR-013 on Average Daily Glucose Levels
The purpose of this study is to evaluate the effect of BKR-013 on average daily glucose (ADG) levels in type 2 diabetes (T2D) subjects during 28 days of either placebo or active test product administration.
- Trial name
- NCT03382015
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- BioKier Inc.
Type1 Diabetes Mellitus
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose.
- Trial name
- NCT02910518
- Testing
- Insulin glulisine (U300), Insulin glulisine, Insulin aspart
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Healthy Subjects
A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions
Primary Objective: To determine the bioequivalence of a single dose of one tablet of sotagliflozin (test) compared to two tablets of sotagliflozin (reference) under fasting conditions in healthy male and female subjects Secondary…
- Trial name
- NCT03776227
- Testing
- sotagliflozin (SAR439954)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects
This study is conducted in Asia. The aim of this observational study is to investigate the percentage of patients reaching the treatment target on blood glucose control after treatment with either human insulin or insulin…
- Trial name
- NCT00806936
- Testing
- human insulin, insulin analogue
- Where
- China
- Volunteers
- 4,847 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart 70 + biphasic insulin aspart 30 with biphasic human insulin 30 in subjects with type 2 diabetes.
- Trial name
- NCT01526980
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70, biphasic human insulin 30
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD)…
- Trial name
- NCT07889505
- Testing
- PS1
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.